Skip to content

Spectrum Pharma buy reiterated by Jefferies

April 13, 2017

Jefferies Group LLC reissued their buy rating on shares of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) in a report issued on Thursday morning. Jefferies Group LLC currently has a $8.50 price target on the biotechnology company’s stock.

Several other research firms have also recently commented on SPPI. Zacks Investment Research cut shares of Spectrum Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, January 11th. FBR & Co set a $11.00 price objective on shares of Spectrum Pharmaceuticals and gave the company a buy rating in a report on Saturday, March 11th. Finally, HC Wainwright set a $10.00 price objective on shares of Spectrum Pharmaceuticals and gave the company a buy rating in a report on Saturday, March 11th. One analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The stock currently has an average rating of Buy and a consensus price target of $8.80.

http://bit.ly/2owdsz8

Advertisements

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: